1 option
Rapid, Site-Specific Labeling of 'Off-the-Shelf' and Native Serum Autoantibodies with T Cell-Redirecting Domains / Fabiana Zappala.
- Format:
- Book
- Thesis/Dissertation
- Author/Creator:
- Zappala, Fabiana, author.
- Language:
- English
- Subjects (All):
- Biology.
- Oncology.
- Immunology.
- Bioengineering--Penn dissertations.
- Penn dissertations--Bioengineering.
- Local Subjects:
- Biology.
- Oncology.
- Immunology.
- Bioengineering--Penn dissertations.
- Penn dissertations--Bioengineering.
- Physical Description:
- 1 online resource (160 pages)
- Distribution:
- Ann Arbor : ProQuest Dissertations & Theses, 2022
- Contained In:
- Dissertations Abstracts International 84-01B.
- Place of Publication:
- [Philadelphia, Pennsylvania] : University of Pennsylvania, 2022.
- Language Note:
- English
- Summary:
- Generating new bispecific antibodies typically requires extensive engineering and cloning. New technologies such as made-to-order genes, advanced expression systems, and high efficiency cloning have simplified and accelerated this process. However, the timeline to create new bispecific antibodies is in the order of months, the resulting yield can be low, and adequate functionality is not guaranteed.Here, we developed a simple method to produce bispecific antibodies by site-specifically and covalently attaching a T cell redirecting domain to any off-the-shelf, human Immunoglobulin G (IgG). Our method excludes antibody engineering, cloning or prior knowledge of the antibody sequence, and the bispecifics are created in two hours. We demonstrated the applicability by assessing in vitro cytolysis of bispecific antibodies made using three FDA-approved monoclonal antibodies.We also show the ability to create personalized T cell redirecting autoantibodies (TRAAbs) by labeling native antibodies isolated from tumor-bearing mice, including two syngeneic murine models. TRAAbs were found to induce anti-tumor effects in vitro and in vivo. TRAAbs were also found to preferentially bind tumor over healthy tissue, highlighting a window for safe therapy. The use of autoantibodies to direct the tumor targeting of bispecific antibodies represents a new paradigm in personalized medicine that eliminates the need to identify tumor biomarkers and can potentially overcome tumor antigen loss, which commonly results from mono-targeted immunotherapies.
- Notes:
- Source: Dissertations Abstracts International, Volume: 84-01, Section: B.
- Advisors: Tsourkas, Andrew; Committee members: Chow, Brian; Chodosh, Lewis; Milone, Michael.
- Department: Bioengineering.
- Ph.D. University of Pennsylvania 2022.
- Local Notes:
- School code: 0175
- ISBN:
- 9798834092476
- Access Restriction:
- Restricted for use by site license.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.